Hodgkin Lymphoma: Is There Really a Need for Interim and End-Of-Treatment FDG-PET Evaluations?

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.14495
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Fact Sheet About Interim and End-Of-Treatment 18 F-FDG PET/CT in Lymphoma

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Reply: Fact Sheet About Interim and End-Of-Treatment 18 F-FDG PET/CT in Lymphoma

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Interim FDG-PET/CT in Hodgkin Lymphoma: What Are We Actually Looking At?

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2018English

Advanced Hodgkin’s Lymphoma: End-Of-Treatment FDG-PET Should Be Maintained

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2017English

Interim FDG-PET Does Not Predict Outcome in Advanced-Stage Hodgkin Lymphoma Patients Treated With BEACOPP

British Journal of Haematology
Hematology
2018English

Interim FDG-PET Has No Value in Selecting Patients Who Require Treatment Modification in Both Early- And Advanced-Stage Hodgkin Lymphoma

British Journal of Haematology
Hematology
2017English

Hodgkin´s Lymphoma and Autoimmunity: Is There a Relationship?

Acta Medica Portuguesa
Medicine
2015English

Interim FDG-PET Has No Value in Selecting Patients Who Require Treatment Modification in Both Early- And Advanced-Stage Hodgkin Lymphoma: Response to Adams and Kwee

British Journal of Haematology
Hematology
2017English

Interim FDG PET Scans in Lymphoma: SUV Measurement Error May Impair qPET Methodology

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy